epocrates logo
epocrates logo
epocrates logo
  • 0

Internally Generated Content

Endocrine Society

Use of semaglutide, tirzepatide, dulaglutide may boost testosterone in men

July 21, 2025

card-image

Use of drugs like semaglutide, tirzepatide, and dulaglutide was linked to an increased proportion of patients who achieved normal testosterone levels, in this EHR review of males with obesity or type 2 diabetes presented at the Endocrine Society’s 2025 annual meeting.

Study details. Researchers examined EHR records for 110 male adults with obesity or type 2 diabetes who were treated with semaglutide, tirzepatide, or dulaglutide; patients weren’t on testosterone or other hormone therapy. Free and total testosterone were measured prior to and during 18 months of treatment.

Results. Patients lost 10% of body weight. The proportion of patients with normal total and free testosterone levels increased from 53% to 77% over the course of the study.

Source:

(2025, July 14). Endocrine Society. Anti-obesity medications can normalize testosterone levels in men [Press release]. https://www.endocrine.org/news-and-advocacy/news-room/endo-annual-meeting/endo-2025-press-releases/portillo-canales-press-release

Trending icon

TRENDING THIS WEEK

EPOCRATES CME

View Catalog

view all CME activities
learn more about epocrates plus
Clinical FAQ icon

Clinical FAQs

Check out the answers to frequently asked questions about our clinical content.

Download Epocrates from the App StoreDownload Epocrates from the Play Store
About UsFeaturesBusiness SolutionsHelp & Feedback
© 2026 epocrates, Inc.   Terms of UsePrivacy PolicyEditorial PolicyDo Not Sell or Share My Information